TURNOVER (x1000 SEK)
NET PROFIT (x1000 SEK)
EMPLOYEES
Prostatype Genomics AB
Closing information (x1000 SEK)
| Closing information | 2024/12 (consolidated) | 2023/12 (consolidated) | 2022/12 |
| Turnover |
199
|
1,356
|
683 |
| Financial expenses |
1,677
|
2,192
|
396 |
| Earnings before taxes |
-41,051
|
-41,435
|
-29,087 |
| EBITDA |
-38,874
|
-37,372
|
-26,786 |
| Total assets |
41,970
|
49,222
|
30,950 |
| Current assets |
11,825
|
25,910
|
14,169 |
| Current liabilities |
8,501
|
24,482
|
4,332 |
| Equity capital |
33,469
|
24,673
|
26,151 |
| - share capital |
670
|
7,168
|
1,372 |
| Employees (average) |
6
|
7
|
6 |
Financial ratios
| Fiscal year | 2024/12 (consolidated) | 2023/12 (consolidated) | 2022/12 |
| Solvency |
79.7%
|
50.1%
|
84.5% |
| Turnover per employee |
33
|
194
|
114 |
| Profit as a percentage of turnover |
-20628.6%
|
-3055.7%
|
-4258.7% |
| Return on assets (ROA) |
-93.8%
|
-79.7%
|
-92.7% |
| Current ratio |
139.1%
|
105.8%
|
327.1% |
| Return on equity (ROE) |
-122.7%
|
-167.9%
|
-111.2% |
| Change turnover |
-1,157
|
673
|
673 |
| Change turnover % | -85% | 6730% | |
| Chg. No. of employees |
-1
|
1
|
1 |
| Chg. No. of employees % | -14% | 20% |
Total value of public sale
| Fiscal year | 2024/12 (consolidated) | 2023/12 (consolidated) | 2022/12 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.